What is CommonQuant (Common Quant)?

CommonQuant, also written Common Quant, is an AI-powered trading platform that turns plain-English market ideas into live, rules-based strategies. It selects relevant instruments, writes indicator-based entry and exit rules, monitors the conditions continuously, and alerts users when conditions are met.

How does CommonQuant generate trading strategies?

You write a natural-language prompt describing your market idea. CommonQuant selects validated instruments, chooses from 20 supported technical indicators, and writes concrete entry and exit rules. The strategy then runs live and sends alerts through the channels available on your plan when conditions trigger.

What markets and instruments does CommonQuant support?

CommonQuant supports several thousand US equities and ETFs listed on Nasdaq, NYSE, NYSE American, and Cboe, plus major crypto assets such as Bitcoin. It does not support FX or futures.

How do I receive trading signal alerts?

CommonQuant provides an in-app signal inbox on all plans. Paid plans add email and Telegram, plus metered monthly SMS and WhatsApp allowances. Channel availability and allowances vary by plan.

Is CommonQuant free to use?

Yes. CommonQuant has a free tier with 1,000 starter credits, 200 monthly refill credits, up to three signal subscriptions, and in-app alerts. Paid plans start at $9/month, and no credit card is required to start.

Does CommonQuant provide financial advice?

No. CommonQuant is a quantitative tool for alpha validation and does not constitute financial advice. Past performance does not guarantee future results. Users are responsible for their own trading decisions.

Can I copy public trading strategies?

Yes. Users can browse, preview, and copy public community and AI-generated strategies into their own accounts. They can also follow strategists and take part in Arena competitions.

CommonQuant.ai Research

AI-generated trading idea · LONG · LLY, TMO, VKTX

Eli Lilly's new weight-loss drug crushes expectations — accumulate pharma suppliers

Eli Lilly just released highly positive results for its new next-generation weight-loss drug. Analysts are impressed, and the stock is jumping as the company proves its entire portfolio of drugs is incredibly strong.

Idea

Eli Lilly's latest drug trial success reinforces its dominance in the massively profitable weight-loss market. Because analysts noted the company's success isn't just built on one single drug, confidence in their entire research pipeline is surging. As the stock builds momentum, it often pulls up the companies that manufacture the drugs and supply the lab equipment, creating a broad buy signal for the sector.

Key details

LLY TMO VKTX1d#pharma#earnings#breakout

Community

Upvotes

Views

Copies

Cosigns

News sources

Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug — MarketWatch
Campbell's Earnings Beat; Eli Lilly Obesity Drug Results | Stock Movers — Bloomberg

Eli Lilly's new weight-loss drug crushes expectations — accumulate pharma suppliers

Idea

Key details

Community

News sources

Related ideas

Related